JMP reiterates $78 target on Cytokinetics stock, sees potential

On Thursday, JMP Securities maintained a positive outlook on Cytokinetics , Inc. (NASDAQ:CYTK) shares, reaffirming a Market Outperform rating and a $78.00 price target. Currently trading at $42.92, with a market capitalization of $5.1 billion, the stock has significant upside potential according to analyst consensus. InvestingPro data shows analyst targets ranging from $47 to $120, with a strong buy consensus recommendation. The firm’s analysts expressed continued confidence in the drug aficamten’s potential to lead its class in treating obstructive hypertrophic cardiomyopathy (oHCM), despite a delay in the regulatory review process by the U.S. Food and Drug Administration (FDA).

Cytokinetics disclosed that the FDA has pushed back the Prescription Drug User Fee Act (PDUFA) goal date for aficamten by three months, setting a new target decision date of December 26, 2025. The extension follows the company’s submission of a Risk Evaluation and Mitigation Strategy (REMS) during the review period, which the FDA categorized as a significant amendment.

JMP analysts view the postponement as a non-issue and continue to support the company’s prospects. They believe that the drug’s label and the REMS program will stand out compared to competitors, particularly CAMZYOS, enhancing aficamten’s profile as the best in its category for treating oHCM.

The REMS program is a drug safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. The submission of such a program can be a critical step in the approval process, ensuring that the drug is used safely and effectively. While the company maintains a strong liquidity position with a current ratio of 6.17 and liquid assets exceeding short-term obligations, InvestingPro analysis indicates the company operates with moderate debt levels.

Cytokinetics’ announcement of the delayed PDUFA date indicates that the company is actively working with the FDA to address any concerns and finalize the necessary components for aficamten’s potential market release. The extended timeline provides additional time for the FDA to review the newly submitted REMS program.

Investors and industry observers will be watching closely as the new PDUFA date approaches, marking a significant milestone for Cytokinetics and the patients who may benefit from aficamten’s approval. The company has demonstrated impressive revenue growth of 145% over the last twelve months, though analysts don’t anticipate profitability this year. For deeper insights into CYTK’s valuation and growth prospects, including exclusive ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.

In other recent news, Cytokinetics has announced that the FDA has extended the review period for its heart drug, aficamten, until December 26, 2025. This extension follows the FDA’s request for a Risk Evaluation and Mitigation Strategy, which the company has since submitted. While the FDA did not request additional clinical data, the review extension is necessary to ensure the drug’s safety and efficacy. Meanwhile, Barclays (LON:BARC) has initiated coverage of Cytokinetics with an Overweight rating and a $55 price target, citing confidence in aficamten’s approval prospects and market potential. H.C. Wainwright has maintained a Buy rating with a $120 target, highlighting the potential positive impact of recent label updates for a competitor’s drug on aficamten’s market adoption. Similarly, Stifel has reiterated a Buy rating and set a target of $87, expressing optimism about aficamten’s differentiation in the cardiomyopathy market. These developments reflect a growing interest and confidence among analysts in Cytokinetics’ lead drug candidate and its future market positioning.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.